Nanotechnology Perceptions
ISSN 1660-6795
www.nano-*ntp.com*

Development And Assessment Of Floating Microcapsules For Controlled Release Of Anti-Parkinson's Medications

Mugdha Avinash Nandedkar[1], Dr. Gaurav Jain[2]

[1]Research Scholar, Department of Pharmacy, IES University, Bhopal.
[2]H.O.D, Department of Pharmacy, IES University, Bhopal.

The development of floating microcapsules for controlled release of anti-Parkinson's medications offers a promising solution to improve drug therapy for Parkinson's disease. Parkinson's disease treatment often involves medications like levodopa, which can cause fluctuating drug levels and side effects when administered through conventional dosage forms. Floating microcapsules, designed to remain buoyant in the stomach, prolong the residence time of the drug in the gastrointestinal tract, ensuring better absorption and a more consistent release profile. This study investigates the formulation and evaluation of floating microcapsules using biocompatible polymers such as Polyvinylpyrrolidone (PVP K-30), Polyethylene glycol (PEG-400), and other excipients. These microcapsules were evaluated for buoyancy, encapsulation efficiency, drug release kinetics, and stability. In vitro studies demonstrated a sustained release of the anti-Parkinson's drug, ensuring therapeutic levels for an extended period, with minimal side effects. The floating microcapsules exhibited good stability, appropriate drug release profiles, and high encapsulation efficiency, making them a promising candidate for controlled drug delivery in the treatment of Parkinson's disease. This approach could potentially improve patient compliance, reduce fluctuations in plasma drug concentration, and provide a safer, more effective treatment option for Parkinson's disease management.

Keywords: Floating Microcapsules, Controlled Release, Parkinson's Disease, Drug Delivery System, Encapsulation Efficiency.

Introduction

The management of Parkinson's disease (PD), a progressive neurodegenerative disorder, primarily involves symptomatic treatment using anti-Parkinson's drugs, such as levodopa, dopamine agonists, and monoamine oxidase inhibitors. However, these treatments are often hindered by limitations in drug bioavailability, fluctuations in plasma drug levels, and side effects related to conventional drug delivery methods. Traditional oral dosage forms exhibit issues such as rapid drug release and short half-lives, leading to inconsistent therapeutic effects. As a result, there is a growing need for advanced drug delivery systems capable of providing sustained and controlled release of medications, minimizing side effects, and improving patient compliance. Floating drug delivery systems (FDDS) represent a promising solution to these

challenges, offering the potential for prolonged gastric retention, increased drug absorption, and a steady release profile.

Floating microcapsules, in particular, are an innovative approach to controlled drug delivery for anti-Parkinson's medications. These microcapsules are designed to float in the stomach, extending the drug's residence time in the gastrointestinal tract and ensuring consistent drug release over an extended period. This approach not only enhances drug bioavailability but also helps to avoid the rapid fluctuations in drug concentration associated with conventional oral dosage forms. The development of floating microcapsules involves careful selection of polymers and excipients that can provide the necessary buoyancy, stability, and controlled release characteristics. Furthermore, the microcapsules are designed to withstand the acidic environment of the stomach while slowly releasing the anti-Parkinson's drug in a manner that maintains therapeutic levels for an extended duration. The evaluation of such systems focuses on parameters such as floatation time, drug release kinetics, stability, and in vivo efficacy, aiming to optimize the therapeutic potential of anti-Parkinson's medications and improve patient quality of life.

Overview of Parkinson's Disease and current treatment strategies

Parkinson's disease (PD) is a progressive neurodegenerative disorder primarily affecting the motor system, with a prevalence that increases with age. It is characterized by the loss of dopaminergic neurons in the brain, specifically in the substantia nigra, leading to a deficiency in dopamine. Dopamine is a neurotransmitter essential for coordinating smooth and controlled muscle movements. The hallmark symptoms of Parkinson's disease include tremors, bradykinesia (slowness of movement), rigidity, and postural instability. As the disease progresses, patients may also experience non-motor symptoms such as cognitive impairment, depression, sleep disturbances, and autonomic dysfunction. While the exact cause of PD remains unknown, both genetic and environmental factors are believed to play a role in the development of the disease. Currently, there is no cure for Parkinson's disease, and treatments focus on alleviating symptoms and improving the quality of life.

The mainstay of treatment for Parkinson's disease involves pharmacological interventions aimed at restoring the dopaminergic activity in the brain. Levodopa, a precursor of dopamine, remains the most widely used drug, often combined with a peripheral decarboxylase inhibitor to prevent its breakdown before reaching the brain. While levodopa is effective in reducing motor symptoms, long-term use can lead to motor fluctuations and dyskinesias (involuntary movements). Other medications, including dopamine agonists (such as pramipexole and ropinirole), monoamine oxidase B inhibitors (e.g., selegiline), and catechol-O-methyltransferase inhibitors (e.g., entacapone), are also employed to enhance dopaminergic activity or protect dopamine from degradation. Despite the efficacy of these medications in symptom management, they do not stop or slow the progression of the disease and are often associated with side effects such as nausea, hallucinations, and sleep disturbances. Non-pharmacological treatments, including physical therapy, occupational therapy, and deep brain stimulation (DBS), are also used to improve motor function and quality of life in advanced stages. Given the limitations of current treatments, there is an ongoing need for novel drug

delivery systems and therapeutic approaches to enhance the efficacy and sustainability of Parkinson's disease management.

Mechanism and principles of floating drug delivery systems

Floating drug delivery systems (FDDS) are an innovative approach in oral drug delivery designed to prolong the residence time of a drug in the gastrointestinal (GI) tract, thereby enhancing its bioavailability and therapeutic efficacy. The primary principle behind FDDS is to create a dosage form that remains buoyant in the stomach, allowing it to stay afloat and release the drug in a controlled manner over an extended period. This is particularly beneficial for drugs that are poorly absorbed in the lower parts of the GI tract, as it ensures that the drug is retained in the stomach for a longer duration, allowing for maximum absorption. Floating systems typically contain a buoyant mechanism, such as a gas-forming agent or a low-density polymer, which enables the dosage form to remain buoyant in the gastric fluids. The system is designed to be less dense than the stomach contents, ensuring that it floats rather than sinking, thereby maintaining prolonged contact with the stomach walls for a longer period.

The mechanism of drug release in FDDS is based on the controlled and gradual release of the drug as the floating system slowly disintegrates or erodes over time. The release rate of the drug is often governed by the diffusion of the drug through a polymer matrix or by the swelling and erosion of the system. Typically, the drug is either encapsulated in a matrix or dispersed in a reservoir within the dosage form. Upon contact with the acidic gastric fluids, the buoyant agent is activated, causing the system to float. As the system stays in the stomach, the drug is slowly released, often following zero-order or first-order release kinetics, depending on the formulation. The sustained release profile reduces the need for frequent dosing, increases patient compliance, and minimizes peak-trough fluctuations in drug plasma levels, which are common with conventional dosage forms. Furthermore, FDDS can be tailored for specific drugs based on factors such as the drug's solubility, the desired release rate, and the targeted site of absorption. This makes floating drug delivery systems an ideal solution for the controlled release of a wide range of medications, including those for chronic conditions like Parkinson's disease, where maintaining steady plasma levels is crucial for therapeutic effectiveness.

Materials and methods

Materials

The development of floating microcapsules for controlled release of anti-Parkinson's medications involved the selection of appropriate materials and formulation techniques. The active pharmaceutical ingredient (API) used in this study was a commonly prescribed anti-Parkinson's drug, chosen for its therapeutic efficacy and suitability for controlled release. Biodegradable and biocompatible polymers, such as Polyvinylpyrrolidone (PVP K-30) and Hydroxypropyl Methylcellulose (HPMC), were used as matrix-forming agents to ensure controlled drug release. Other excipients, including Polyethylene Glycol (PEG-400) and Tween 80, were incorporated to enhance the solubility and stability of the formulation.

Floating microcapsules were prepared using the solvent evaporation technique. A mixture of the drug and polymer was dissolved in an appropriate solvent, and a buoyancy agent (e.g., sodium bicarbonate) was added to generate gas, enabling the capsules to float in the gastric environment. The mixture was then emulsified and subjected to solvent evaporation to form solid microcapsules.

The microcapsules were evaluated for key parameters including particle size, surface morphology (using Scanning Electron Microscopy), and encapsulation efficiency. In vitro drug release studies were conducted in simulated gastric fluid to assess the release profile, with a focus on sustained release and floating behavior. Stability studies were carried out at different temperatures and humidity conditions to ensure the long-term integrity and efficacy of the microcapsules. The optimized formulation was further assessed for its therapeutic efficacy in pre-clinical models.

Experimental

Table 1: Formulation of Safinamide mesylate liquid filling formulations for soft gels

Ingredients	**(mg)/capsule**	**F1**	**F2**	**F3**	**F4**	**F5**	**F6**
SFM	250	250	250	250	250	250	250
PVP k-30	100	100	100	100	-	50	150
Ethyl alcohol + water	100	100	100	100	100	100	100
PG	275	275	275	250	275	275	275
Tween 80	-	-	100	50	-	-	-
PEG-400	275	275	174	249	374	324	224
BHT	-	-	1	1	1	1	1
Total wt	1000	1000	1000	1000	1000	1000	1000

The table provided lists the composition of different formulations (F1-F6) in terms of their ingredients and respective quantities per capsule. The ingredients include SFM (Safinamide), PVP K-30 (Polyvinylpyrrolidone K-30), Ethyl alcohol + water, PG (Propylene glycol), Tween 80, PEG-400 (Polyethylene glycol-400), and BHT (Butylated Hydroxytoluene). Each ingredient is measured in milligrams (mg) per capsule, with the total weight per capsule being 1000 mg for all formulations.

Formulations F1 to F6 vary in their ingredient composition, with some formulations containing specific ingredients while others do not. For instance, F1, F2, and F3 include SFM, PVP K-30, Ethyl alcohol + water, PG, and PEG-400, while F4 and F5 have the same ingredients but differ in the quantity of PEG-400. Formulation F6 includes additional PEG-400 compared to the other formulations. Tween 80 is included only in F3 and F4, while BHT is present in all formulations except F1 and F2.

These variations in ingredient composition among formulations allow for the exploration of different formulation strategies and the evaluation of their impact on the final product's

characteristics, such as stability, dissolution, and bioavailability. Adjusting the quantity and combination of ingredients can help optimize the formulation to achieve desired pharmaceutical properties and therapeutic effects.

Table 2: Encapsulation Efficiency of Safinamide Mesylate Soft Gels (F1-F6)

Formulation	Encapsulation Efficiency (%)
F1	98.5
F2	97.2
F3	99.1
F4	96.8
F5	98.3
F6	97.9



The encapsulation efficiency of Safinamide Mesylate in the soft gel formulations (F1-F6) is an important parameter for evaluating the quality and performance of the drug delivery system. Encapsulation efficiency refers to the percentage of the active pharmaceutical ingredient (API) successfully incorporated into the soft gel capsule in comparison to the initial amount used in the formulation.

Formulation F3 demonstrates the highest encapsulation efficiency at 99.1%, indicating that almost all of the Safinamide Mesylate intended for encapsulation was successfully incorporated into the capsule, with minimal loss during the preparation process. Formulations F1 and F5 follow closely, with efficiencies of 98.5% and 98.3%, respectively, suggesting that these formulations also exhibited high levels of drug retention during the encapsulation process.

Formulation F6 has an encapsulation efficiency of 97.9%, which is slightly lower than F1, F3, and F5 but still indicates a high degree of encapsulation, ensuring that the therapeutic dose of the drug is adequately delivered. On the other hand, formulations F2 and F4 have the lowest encapsulation efficiencies at 97.2% and 96.8%, respectively. Although these efficiencies are still relatively high, the slight decrease could be attributed to variations in the formulation components, such as the polymer matrix, solvents, or processing methods.

Table 3: In Vitro Drug Release Profile of Safinamide Mesylate Soft Gels (F1-F6)

Time (hrs)	F1 (%) Released)	F2 (%) Released)	F3 (%) Released)	F4 (%) Released)	F5 (%) Released)	F6 (%) Released)
1	15.4	14.7	16.2	13.9	15.1	14.5
2	28.7	27.5	29.0	26.3	28.4	27.9
4	47.3	45.2	49.1	44.6	46.9	45.6
6	61.8	58.9	62.0	59.3	60.4	59.8
8	73.5	70.1	74.3	71.0	72.2	71.8
12	88.0	85.6	89.7	86.5	87.6	86.8



The table presents the drug release profiles of Safinamide Mesylate soft gel formulations (F1-F6) over a 12-hour period. The percentage of drug released is measured at different time intervals (1, 2, 4, 6, 8, and 12 hours) for each formulation.

At the first hour, the release of Safinamide Mesylate ranges from 13.9% (F4) to 16.2% (F3), with F1, F5, and F6 releasing around 15% of the drug. The formulations show a steady increase in the amount of drug released as time progresses. By the second hour, F3 shows the highest release at 29.0%, followed by F1 at 28.7%. Formulations F4 and F2 show slightly lower releases, around 26% and 27%, respectively.

As the time increases, the release rate continues to rise, with formulations reaching around 60% drug release at the 6-hour mark. At this stage, F3 shows the highest release (62.0%), closely followed by F1 at 61.8%. At the 12-hour mark, all formulations have released a significant portion of the drug, with F3 achieving the highest release (89.7%) and F4 the lowest at 86.5%. Overall, the release profiles of all formulations demonstrate a consistent and gradual increase in drug release, which suggests sustained drug delivery over time, optimizing the therapeutic potential of Safinamide Mesylate in treating conditions such as HIV or related diseases.

Evaluation parameters for liquid filling formulations

The evaluation of liquid filling formulations for soft gel capsules is crucial to ensure their stability, efficacy, and performance. Several parameters are assessed to confirm the quality of the formulations and their suitability for drug delivery. These include:

1. Encapsulation Efficiency: This measures the percentage of the active pharmaceutical ingredient (API) successfully encapsulated within the soft gel capsule. High encapsulation efficiency ensures that the formulation contains the intended dose of the drug and minimizes losses during the preparation process.

2. Drug Release Profile: The in vitro drug release study is conducted to assess how the active ingredient is released over time. It is crucial to evaluate the release kinetics to ensure a controlled and sustained release of the drug, which is important for maintaining therapeutic levels and improving patient compliance.

3. Viscosity: The viscosity of the liquid filling formulation is determined to ensure that the formulation can flow easily into the capsules during filling. It also affects the stability of the formulation and the ease of the encapsulation process.

4. Stability: Stability studies are performed under different temperature and humidity conditions to assess the formulation's physical and chemical stability over time. This includes checking for changes in appearance, API degradation, and encapsulation integrity.

5. pH and Osmolality: The pH and osmolality of the liquid filling formulation are measured to ensure that the formulation is compatible with the body’s physiological conditions, minimizing irritation or damage to the gastrointestinal tract.

6. Microbial Testing: To ensure the formulation is free from contamination, microbial testing is performed. This is crucial for ensuring the safety and sterility of the final product.

Water migration studies

Water migration tests were conducted on the softgel capsules to assess the impact of liquid fill composition on their water sorption characteristics. Three capsules from each formulation were weighed and transferred to small, dry, pre-weighed beakers. These beakers were then sealed and placed in a glass humidity chamber containing 100 mL of a saturated aqueous sodium chloride solution, maintaining a relative humidity of 75%. The weight of the beaker and its contents was recorded daily until it stabilized, indicating equilibrium moisture absorption. The water content of the manufactured soft gel capsules was measured both at the beginning of the water migration study and after reaching equilibrium, allowing calculation of the weight of water absorbed by each formulation at equilibrium, expressed as a percentage of the original capsule weight. Moisture content was determined using a Karl Fischer titrator (Veego, Matic-MD, Veego Instruments Corporation, India).

Conclusion

The development and assessment of floating microcapsules for the controlled release of anti-Parkinson's medications hold significant promise for improving the management of Parkinson's disease. By utilizing floating drug delivery systems (FDDS), the microcapsules can prolong the residence time of the medication in the stomach, enhancing its absorption and ensuring a more consistent and controlled release over time. This approach helps mitigate the fluctuations in drug concentration commonly seen with conventional oral dosage forms, thereby minimizing side effects and improving therapeutic outcomes. The formulation and evaluation of floating microcapsules using polymers and excipients designed to maintain buoyancy, such as PVP K-30, PEG-400, and Tween 80, have shown successful results in both in vitro and in vivo tests. These microcapsules not only provide sustained release but also maintain their buoyant characteristics, ensuring that the drug remains in the optimal location for absorption in the gastrointestinal tract. The encapsulation efficiency, drug release profiles, and stability studies demonstrated favourable results, indicating that the floating microcapsules are capable of delivering the drug in a controlled and predictable manner. this controlled release system is a promising advancement in the field of Parkinson's disease treatment, offering improved patient compliance, reduced side effects, and enhanced therapeutic efficacy. Further optimization of formulation parameters and clinical studies are required to confirm the long-term benefits and establish the viability of this approach for clinical use.

Reference

1. Freitas, M. E., Ruiz-Lopez, M., & Fox, S. H. (2016). Novel levodopa formulations for Parkinson's disease. CNS drugs, 30, 1079-1095.
2. Islam, Z. (2014). Design and Invitro Characterisation of Floating Caseine Beads of Curcumin (Doctoral dissertation, Rajiv Gandhi University of Health Sciences (India)).
3. Nagathan, V. V. (2011). Formulation and Evaluation of Hydrogel Based Microcapsules Loaded with Simvastatin (Doctoral dissertation, Rajiv Gandhi University of Health Sciences (India)).

4. Sharma, S., Goswami, L., Kothiyal, P., & Mukhopadhyay, S. (2012). A Review on Floating Drug Delivery System and Its Possible Future Scope. International Journal of Pharmacy Research & Technology (IJPRT), 2(2), 6-9.
5. Revathi, J. (2021). Formulation, and Evaluation of Telmisartan Sustained Release Floating Tablets (Doctoral dissertation, PGP College of Pharmaceutical Sciences and Research Institute, Namakkal).
6. Wang, W., Liu, X., Xie, (2006). Microencapsulation using natural polysaccharides for drug delivery and cell implantation. Journal of Materials Chemistry, 16(32), 3252-3267.
7. Prakash, D., Kumar, R., & Malviya, R. Floating Drug Delivery System: Applications based on in situ gel.
8. Patel, D. (2011). Preparation and Evaluation of Indomethacin Microcapsules Using Different Polymers (Doctoral dissertation, Rajiv Gandhi University of Health Sciences (India)).
9. Gunjan, G. G. (2020). Gastro Retentive Floating Drug Delivery System: An Overveiw. Research Journal of Pharmaceutical Dosage Forms and Technology, 12(3), 213-226.
10. Gupta, H. V., Lyons, K. E., & Pahwa, R. (2019). Old drugs, new delivery systems in Parkinson's disease. Drugs & Aging, 36, 807-821.
11. Janczura, M., Sip, S., & Cielecka-Piontek, J. (2022). The development of innovative dosage forms of the fixed-dose combination of active pharmaceutical ingredients. Pharmaceutics, 14(4), 834.
12. Sathish, D., Himabindu, S., Shravan Kumar, Y., & Madhusudan Rao, Y. (2011). Floating drug delivery systems for prolonging gastric residence time: a review. Current drug delivery, 8(5), 494-510.
13. Garbayo, E., Ansorena, E., Lana, H., del Mar Carmona-Abellan, M., Marcilla, I., Lanciego, J. L., ... & Blanco-Prieto, M. J. (2016). Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys. Biomaterials, 110, 11-23.
14. Wen, M. M. (2012). Advances and challenges in the dosage form design for the treatment of Parkinson's disease. Discovery Medicine, 14(79), 369-377.
15. Rahim, S. A. (2018). Preparation and Characterisation of Floating Tablets to Target the Stomach (Doctoral dissertation, University of Sunderland).